Tamar Peretz‐Yablonski

Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)

Thomas Bachelot, Eva Ciruelos, Fabio Puglisi et al. · Annals of Oncology · 2019 · 113 citations · Full text

Medicine, Oncology, Pharmacology +17

Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication

David Miles, Eva Ciruelos, Fabio Puglisi et al. · Annals of Oncology · 2021 · 89 citations · Full text

Medicine, Oncology, Pharmacology +17

Pregnancy After Breast Cancer in Young <i>BRCA </i>Carriers

Matteo Lambertini, Eva Blondeaux, Elisa Agostinetto et al. · JAMA · 2023 · 54 citations · Full text

Medicine, Obstetrics, Oncology +16

A phase 1 study of intravenous mitazalimab, a CD40 agonistic monoclonal antibody, in patients with advanced solid tumors

Víctor Moreno, Ruth Perets, Tamar Peretz‐Yablonski et al. · Investigational New Drugs · 2022 · 26 citations

Medicine, Oncology, Pharmacology +15

Safety of assisted reproductive techniques in young women harboring germline pathogenic variants in BRCA1/2 with a pregnancy after prior history of breast cancer

M. Condorelli, Marco Bruzzone, Marcello Ceppi et al. · ESMO Open · 2021 · 21 citations · Full text

Medicine, Gynecology, Oncology +12